Cytotoxicity of combinations of the pan-KRAS inhibitor BAY-293 against primary non-small lung cancer cells

Cytotoxicity of combinations of the pan-KRAS inhibitor BAY-293 against primary non-small lung cancer cells

KRAS is mutated in approximately 25% of Non-small Cell Lung Cancer (NSCLC) patients and first specific inhibitors showed promising responses that may be improved by concurrent interference with downstream signaling pathways. Cell lines exhibiting KRAS mutations show specific sensitivities to modulat...

Full description

Bibliographic Details
Main Authors: Adelina Plangger, Barbara Rath, Maximilian Hochmair, Martin Funovics, Gerhard Hamilton
Format: Article
Language:English
Published: Elsevier 2021-12-01
Series:Translational Oncology
Subjects:
Non-small cell lung cancer
KRAS inhibitor
BAY-293
Drug combination
Osimertinib
Cytotoxicity
Online Access:http://www.sciencedirect.com/science/article/pii/S1936523321002229

Internet

http://www.sciencedirect.com/science/article/pii/S1936523321002229

Similar Items